The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Novikova E.S.

Moscow Regional Research and Clinical Institute («MONIKI»)

Experience with the use of risdiplam in a familial case of spinal muscular atrophy 5q in patients with a homozygous deletion of the SMN1 gene and the same copy number of the SMN2 gene

Authors:

Novikova E.S.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(5): 138‑141

DOI: 10.17116/jnevro2024124051138

Views: 935

Downloaded: 17

Download PDF (RU)
Contact the author
Table of contents

EXPERIENCE WITH THE USE OF RISDIPLAM IN A FAMILIAL CASE OF SPINAL MUSCULAR ATROPHY 5Q IN PATIENTS WITH A HOMOZYGOUS DELETION OF THE SMN1 GENE AND THE SAME COPY NUMBER OF THE SMN2 GENE
EXPERIENCE WITH THE USE OF RISDIPLAM IN A FAMILIAL CASE OF SPINAL MUSCULAR ATROPHY 5Q IN PATIENTS WITH A HOMOZYGOUS DELETION OF THE SMN1 GENE AND THE SAME COPY NUMBER OF THE SMN2 GENE

To cite this article:

Novikova ES. Experience with the use of risdiplam in a familial case of spinal muscular atrophy 5q in patients with a homozygous deletion of the SMN1 gene and the same copy number of the SMN2 gene. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(5):138‑141. (In Russ.)
https://doi.org/10.17116/jnevro2024124051138

 
 
Подписка 2025-2 (S.S. Korsakov Journal of Neurology and Psychiatry)
 
МСФ на ЯМ
Close metadata
Recommended articles:
Promising approaches to the pathogenetic therapy of amyotrophic late­ral scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):13-21
Long-term follow-up of adult patients with serial and status course of epileptic seizures. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):63-68
Expe­rience of the treatment of spinal muscular atro­phy type 3 Kuge­lberg—Welander with Nusi­nersen. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):153-158
Effi­cacy and safety of choline alfo­scerate in the preventive therapy of deme­ntia in elde­rly patients with Mild Cognitive Impairment: a three-year prospective comparative study. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):92-99
B vita­mins and diseases of the peri­pheral nervous system. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):75-82
Asthenia in young patients and possibilities for its correction. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):133-137
Traumatic damage to the diaphragm in children. Piro­gov Russian Journal of Surgery. 2024;(4):64-68
Use of systemic steroids in hospitalized patients with COVID-19. Russian Journal of Preventive Medi­cine. 2024;(5):75-80
Our expe­rience in the treatment of congenital nasal median hete­rotopias in children and an overview of various treatment tactics. Russian Bulletin of Otorhinolaryngology. 2024;(2):28-32
Clinical and anatomical rationale for the effe­ctiveness of treatment of phle­gmon of the floor of the oral cavity and deep cellular spaces of the neck complicated with sepsis. Russian Journal of Operative Surgery and Clinical Anatomy. 2024;(2):19-25

Advances in the treatment of spinal muscular atrophy (SMA) have revolutionized the field. SMA is a rare autosomal recessive neurodegenerative motor neuron disease in which wide phenotypic variability has been described. The rate of increase in neurological deficit and the severity of the disease is mainly determined by the amount of functional SMN (Survival of Motor Neuron) protein. However, the clinical picture may differ significantly in patients carrying homozygous deletions of the SMN1 gene (Survival of Motor Neuron 1) and an identical number of copies of the SMN2 gene (Survival of Motor Neuron 2). A family clinical case of adult patients with spinal muscular atrophy 5q with a homozygous deletion of the SMN1 gene and the same number of copies of the SMN2 gene, having a different clinical picture of the disease, is presented, and the dynamics of the condition against the background of oral pathogenetic therapy is presented.

Keywords:

spinal muscular atrophy
SMN1 gene
SMN2 gene
treatment
risdiplam

Authors:

Novikova E.S.

Moscow Regional Research and Clinical Institute («MONIKI»)

Received:

13.02.2024

Accepted:

14.02.2024

List of references:

  1. Gavriilaki M, Moschou M, Papaliagkas V, et al. Biomarkers of disease progression in adolescents and adults with 5q spinal muscular atrophy: a systematic review and meta-analysis. Neuromuscul Disord. 2022;32(3):185-194.  https://doi.org/10.1016/j.nmd.2021.12.005
  2. Novikova ES. Experience of using oral pathogenetic therapy with the drug risdiplam in adult patients with spinal muscular atrophy 5q in the Moscow region. Annals of Clinical and Experimental Neurology. 2023;17(3):88-93. (In Russ.). https://doi.org/10.54101/ACEN.2023.3.11
  3. McCluskey G, Lamb S, Mason S, et al. Risdiplam for the treatment of adults with spinal muscular atrophy: Experience of the Northern Ireland neuromuscular service. Muscle Nerve. 2023;67(2):157-161.  https://doi.org/10.1002/mus.27755
  4. Schön M, Domingues S, Moreno T, et al. A severely affected adult type 2 spinal muscular atrophy patient treated with risdiplam. Neurol Sci. 2023;44(4):1449-1450. https://doi.org/10.1007/s10072-022-06539-1
  5. Wirth B, Brichta L, Schrank B, et al. Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number. Hum Genet. 2006;119(4):422-428.  https://doi.org/10.1007/s00439-006-0156-7
  6. Lefebvre S, Bürglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;13:80(1):155-165.  https://doi.org/10.1016/0092-8674(95)90460-3
  7. Burghes A, Beattie C. Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick? Nat Rev Neurosci. 2009;10(8):597-609.  https://doi.org/10.1038/nrn2670
  8. Zhou C, Feng Z, Ko CP. Defects in Motoneuron-Astrocyte Interactions in Spinal Muscular Atrophy. J Neurosci. 2016;24:36(8):2543-2553. https://doi.org/10.1523/JNEUROSCI.3534-15.2016
  9. Gabanella F, Butchbach ER, Saieva L, et al. Ribonucleoprotein assembly defects correlate with spinal muscular atrophy severity and preferentially affect a subset of spliceosomal snRNPs. PLoS One. 2007;26:2(9):e921. https://doi.org/10.1371/journal.pone.0000921
  10. Workman E, Saieva L, Carrel TL, et al. A SMN missense mutation complements SMN2 restoring snRNPs and rescuing SMA mice. Hum Mol Genet. 2009;15:18(12):2215-2229. https://doi.org/10.1093/hmg/ddp157
  11. Oprea GE, Kröber S, McWhorter ML, et al. Plastin 3 is a protective modifier of autosomal recessive spinal muscular atrophy. Science. 2008;320(5875):524-527.  https://doi.org/10.1126/science.1155085
  12. Akhkiamova MA, Shchagina OA, Polyakov AV. Factors modifying the course of spinal muscular atrophy 5q. Neuromuscular Diseases. 2023;13(4):62-73. (In Russ.). https://doi.org/10.17650/2222-8721-2023-13-62-73
  13. Cintas P. Current treatments of spinal muscular atrophy in adults. Rev Neurol (Paris). 2023;179(1-2):106-113.  https://doi.org/10.1016/j.neurol.2022.12.003
  14. Hagenacker T, Wurster CD, Günther R, et al. Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study. Lancet Neurol. 2020;19(4):317-325.  https://doi.org/10.1016/S1474-4422(20)30037-5
  15. Pane M, Coratti G, Pera MC, et al. Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophy. Ann Clin Transl Neurol. 2022;9(3):404-409.  https://doi.org/10.1002/acn3.51514
  16. Chiriboga CA, Bruno C, Duong T, et al. Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study [published correction appears in Neurol Ther. 2023 Oct;12(5):1799-1801]. Neurol Ther. 2023;12(2):543-557.  https://doi.org/10.1007/s40120-023-00444-1
  17. Günther R, Neuwirth C, Koch JC, et al. Motor Unit Number Index (MUNIX) of hand muscles is a disease biomarker for adult spinal muscular atrophy. Clin Neurophysiol. 2019;130(2):315-319.  https://doi.org/10.1016/j.clinph.2018.11.009
  18. Sun J, Harrington MA, Porter B; TREAT-NMD Global Registry Network for SMA. Sex Difference in Spinal Muscular Atrophy Patients — are Males More Vulnerable? J Neuromuscul Dis. 2023;10(5):847-867. 
  19. Günther R, Wurster CD, Cordts I, et al. Patient-Reported Prevalence of Non-motor Symptoms Is Low in Adult Patients Suffering From 5q Spinal Muscular Atrophy. Front Neurol. 2019;1:10:1098. https://doi.org/10.3389/fneur.2019.01098
  20. Kessler T, Sam G, Wick W, et al. Evaluation of risdiplam efficacy in 5q spinal muscular atrophy: A systematic comparison of electrophysiologic with clinical outcome measures. Eur J Neurol. 2023;12:23-29.  https://doi.org/10.1111/ene.16099
  21. Shpilyukova YuA, Illarioshkin SN. Spinal muscular atrophy in adults: problems of early diagnosis. Neuromuscular Disease. 2022;12(4):37-45. (In Russ.). https://doi.org/10.17650/2222-8721-2022-12-4-37-45
  22. Wirth B, Mendoza-Ferreira N, Torres-Benito L. Spinal muscular atrophy disease modifiers. Spinal Muscular Atrophy Disease Mechanisms and Therapy. 2020;12:191-210.  https://doi.org/10.1016/B978-0-12-803685-3.00012-4
  23. Shpilyukova YuA, Klyushnikov SA, Illarioshkin SN. Use of oral pathogenetic therapy with risdiplam in adult patients with spinal muscular atrophy. Nervous Diseases. 2023;4:3-11. (In Russ.). https://doi.org/10.24412/2226-0757-2023-13040

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.